FOI 1635 – Community Dermatology Services
FOI Reference Number:
1635
Request
Q1. Does the Integrated Care Board commission Community Dermatology Services? If yes, what was the total number of patients treated by the Community Dermatology Providers in the last 12 months?
Q2. Who are the Community Dermatology Service Providers commissioned by the Integrated Care Board? Can you please provide the number of patients treated by each provider within the last 12 months?
Q3. Do the Community Dermatology Service providers treat patients with any of the following drug types?
· Monoclonal antibody drugs (e.g. Adalimumab, Dupilumab, Secukinumab, Ustekinumab)
· JAK inhibitors (e.g. Abrocitinib, Baricitinib)
Q4. Do the Community Dermatology Service providers initiate treatment with any of the following drug types?
· Monoclonal antibody drugs (e.g. Adalimumab, Dupilumab, Secukinumab, Ustekinumab)
· JAK inhibitors (e.g. Abrocitinib, Baricitinib)
Response
Date: 12 August 2022
FREEDOM OF INFORMATION – DECISION NOTICE
Dear Sir / Madam,
FOI Reference Number: 1234
Q1. Does the Integrated Care Board commission Community Dermatology Services? If yes, what was the total number of patients treated by the Community Dermatology Providers in the last 12 months?
Yes. Please see below for the information we hold with regards to the numbers of patients.
Q2. Who are the Community Dermatology Service Providers commissioned by the Integrated Care Board? Can you please provide the number of patients treated by each provider within the last 12 months?
• University Hospitals Derby and Burton NHS Foundation Trust (UHDB)
Total activity over last 12 months: 2,038
Please note: with regards to the information held by the providers listed below, we hold information relating to the number of claims rather than the number of patients.
• Chatsworth Road Medical Centre
Total claims over last 12 months: 424 first appointments
• Stubley Medical Centre
Total claims over last 12 months: 165 first appointments
• The Valleys Medical Partnership
Total claims over last 12 months: 239 first appointments
• Bakewell Medical Centre
Total claims over last 12 months: 316 first appointments
Q3. Do the Community Dermatology Service providers treat patients with any of the following drug types?
· Monoclonal antibody drugs (e.g. Adalimumab, Dupilumab, Secukinumab, Ustekinumab)
· JAK inhibitors (e.g. Abrocitinib, Baricitinib)
I can confirm that we do not treat or initiate using the drugs listed.
Q4. Do the Community Dermatology Service providers initiate treatment with any of the following drug types?
· Monoclonal antibody drugs (e.g. Adalimumab, Dupilumab, Secukinumab, Ustekinumab)
· JAK inhibitors (e.g. Abrocitinib, Baricitinib)
I can confirm that we do not treat or initiate using the drugs listed.
I hope that this answers your queries with the information we currently hold, but if I can be of any further assistance please do not hesitate to contact me.
If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:
NHS Derby and Derbyshire ICB
FOI Team
Scarsdale
Nightingale Close
Newbold
Chesterfield
S41 7PF
Or:
If you are not content with the outcome of our review, you may apply directly to the Information Commissioner for a decision. Generally, the ICO cannot make a decision unless you have exhausted the complaints procedure provided by the Derby and Derbyshire Integrated Care Board (ICB).
The Information Commissioner can be contacted at: Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF, telephone 0303 123 1113, email casework@ico.org.uk.
Yours faithfully,
Kathryn Jacklin
FOI Officer
Derby and Derbyshire ICB
All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for re-use under the Open Government Licence (OGL) a request to re-use is not required, but the licence conditions must be met. You must not re-use any previously unreleased information without having the consent from the ICB. Should you wish to re-use previously unreleased information then you must make your request in writing (email will suffice) to the FOI Lead via ddicb.foi@nhs.net. All requests for re-use will be responded to within 20 working days of receipt.